2Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor based therapies. Clin Pharmacokinet, 2005, 44: 441-466.
3Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res, 2001, 18; 721-727.
4Ishizawa Y, Yasui Furukori N, Takahata T, et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmaeokineties. Clin Pharmacokinet, 2005, 44:1179-1189.
7Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther, 2001, 15:1479 1484.
8Lee SB, Park SJ, Ryu JK, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J Gastroenterol, 2003, 42: 468- 475.
9Hassan Alin M, Andersson T, Niazi M, et al. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther, 2006, 44: 119-127.
10Hamajima N. Persistent Helicobacter pylori infection and genetic polymorphisms of the host. Nagoya J Med Sci, 2003, 66: 103- 117.
3Furuta T,EI-Omar E M, Xiao F,et al. lnterleukin 1 beta polymorphisms increase risk of hypoehlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan[J]. Ga.stroenterology,2002,123( 1 ) :92 - 105.
4Hsu P I,Li C N,Tseng H H,et al. The interleukin-1 RN polymorphism and Helicobacter pylori infection in the development of duodenal ulcer [ J ]. Helicobacter, 2004,9 ( 6 ) : 605 - 13.
5Zambon C F, Basso F, Navaglia F, et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1 beta genes interplay in favoring the development of peptic ulcer and intestinal metaplasia[ J ]. Cytokin,2002,18 (5) :242 - 51.
6Li C, Xia H H, Xie W, et al. Association between interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric carcinogensis in a Chinese population [ J ]. J Gastroentroenterol Hepatol,2007,22(2) :234-9.
7Kim N, Cho S I, Yim J Y, et al. The effects of genetic polymorphisms of IL-1 and TNF - A on Helicobacter pylori - induced gastroduodenal diseases in Korea [ J ]. Helicobacter,2006,11 ( 2 ) : 105 -12.
8Garcia-Gonzalez M A, Lanas A, Savelkoul P H, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease[J]. Clinical and Experimental Immunology,2003,134(3 ): 525 - 31.
9Blaser M J. Linking Helicobacter pylori to gastric cancer[ J]. Nature Med,2000,6(4) :376 -7.
10Watanabe T, Higuchi K, Tominaga K, et al. Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin lbeta[J]. Gut,2001,48(6) :774 -81.
1Pilotto A, Franceschi M, Maggi S, et al. Optimal management of pep- tic ulcer disease in the elderly [ J ]. Drugs and aging, 2010,27 (7) : 545-558.
2Huang K W, Luo J C, Leu H B, et al. Chronic obstructive pulmonary disease:An independent risk factor for peptic ulcer bleeding:A na- tionwide population - based study [ J ]. Alimentary Pharmacology and Therapeutics ,2012,35 (7) :796-802.
3Wychowski M K, Kouides P A. Dabigatran - induced gastrointestinal bleeding in an elderly patient with moderate renal impairment [ J ]. The annals of pharmacotherapy,2012,46(4) :el0.
4Kang J M, Kim N, Lee B H, et al. Risk factors for peptic ulcer bleed- ing in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents [ J]. Scandinavian Journal of Gastroenterology ,2011,46 ( 11 ) : 1295- 1301.
5Onasanwo S A, Singh N, Olaleye S B, et al. Anti - ulcer & ; an- tioxidant activities of Hedranthera barteri { ( Hook R) Pichon I with possible involvement of H - , K - ATPase inhibitory activity [ J ]. The Indian journal of medical research,2010,132(4) :442-449.
6Hirotaka Sekiguchi, Fumiyo Takabayashi, Yuya Deguchi, et al. Leaf Extract of Wasabia japonica Relieved Oxidative Stress Induced by Helicobacter pylori Infection and Stress Loading in Mongolian Ger- bils [ J 1. B ioscience, B iotechnology and Biochemistry, 2010,74 ( 6 ) : 1194-1199.
7Gisbert JP,Calvet X. Review article:non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori[J].{H}Alimentary Pharmacology and Therapeutics,2011,(6):604-617.
8Wu DC,Hsu PI,Wu JY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection[J].{H}Clinical Gastroenterology and Hepatology,2010,(1):36-41.
